Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results in 2025, volatility was elevated, and sentiment shifted frequently, influenced by political developments in the US, evolving trade policy rhetoric, changing expectations for monetary policy, and ongoing geopolitical tensions. Against this backdrop, the Fund posted strong absolute returns in the fourth quarter, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index. The portfolio delivered strong results in the quarter across all segments. In contrast, for the full year, the Fund generated strong results but trailed both the indexes. In Q4 2025, the market leadership shifted back to companies with durable profit cycles. Moving to 2026, the firm continues to focus on its proven technique of identifying profit cycles in franchise companies at reasonable valuations. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Artisan Small Cap Fund highlighted Insmed Incorporated (NASDAQ:INSM) as one of its leading contributors. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focusing on developing therapies for patients with serious and rare diseases. On March 16, 2026, Insmed Incorporated (NASDAQ:INSM) stock closed at $144.60 per share. One-month return of Insmed Incorporated (NASDAQ:INSM) was -3.93%, and its shares gained 87.82% over the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $31.17 billion.
Artisan Small Cap Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its fourth quarter 2025 investor letter:
“Our top contributors in Q4 were MACOM Technology Solutions, Insmed Incorporated (NASDAQ:INSM) and Vita Coco. Insmed is a biotechnology company focused on pulmonary diseases. We exited our position during the quarter due to market cap considerations, though the stock remained a top performer. Its strength was driven by the successful launch of Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, which generated $28 million in initial sales from roughly 2,500 patients and 1,700 prescribers, along with a robust pipeline of additional potential therapies.”
Insmed Incorporated (NASDAQ:INSM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 75 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the fourth quarter, up from 73 in the previous quarter. While we acknowledge the risk and potential of Insmed Incorporated (NASDAQ:INSM) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Insmed Incorporated (NASDAQ:INSM) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Insmed Incorporated (NASDAQ:INSM) and shared the list of stocks that could skyrocket in 2026. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
